Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ORAI1 | Q96D31 | 7/20 | 1.00 |
| ▸ | CRACR2A | Q9BSW2 | 11/20 | 0.62 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1893000 | 0.88 | ORAI1 (1.00) | ORAI1CRACR2ANPC1RAB9A | |
| SCHEMBL30096527 | 0.88 | ORAI1 (1.00) | ORAI1CRACR2ANPC1RAB9A | |
| SCHEMBL1896340 | 0.88 | ORAI1 (0.79) | ORAI1CRACR2ANPC1RAB9A | |
| SCHEMBL1890023 | 0.87 | ORAI1 (1.00) | ORAI1CRACR2ANPC1RAB9A | |
| SCHEMBL30308394 | 0.87 | ORAI1 (0.77) | ORAI1CRACR2A | |
| SCHEMBL1889401 | 0.87 | ORAI1 (0.77) | ORAI1CRACR2A | |
| SCHEMBL12661310 | 0.86 | ORAI1 (0.81) | ORAI1CRACR2ANPC1RAB9A | |
| SCHEMBL1670240 | 0.86 | ORAI1 (0.77) | ORAI1CRACR2A | |
| SCHEMBL30096554 | 0.86 | ORAI1 (0.77) | ORAI1CRACR2A | |
| SCHEMBL1668844 | 0.85 | ORAI1 (1.00) | ORAI1CRACR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113557020-A | Compositions comprising CRAC inhibitors and corticosteroids and methods of use thereof | 瑞真药业公司 | 2021-10-26 | — | — | CN | claimed |
| EP-3849552-A1 | COMPOSITIONS COMPRISING A CRAC INHIBITOR AND A CORTICOSTEROID AND METHODS OF USE THEREOF | Rhizen Pharmaceuticals AG (CH) | 2021-07-21 | — | — | EP | claimed |
| WO-2020053834-A1 | COMPOSITIONS COMPRISING A CRAC INHIBITOR AND A CORTICOSTEROID AND METHODS OF USE THEREOF | RHIZEN PHARMACEUTICALS SA (CH) | 2020-03-19 | — | — | WO | claimed |
| US-20190248791-A1 | NOVEL MODULATORS OF CALCIUM RELEASE-ACTIVATED CALCIUM CHANNEL AND METHODS FOR TREATMENT OF NON-SMALL CELL LUNG CANCER | RHIZEN PHARMACEUTICALS SA (CH) | 2019-08-15 | — | — | US | claimed |
| US-10174034-B2 | Modulators of calcium release-activated calcium channel and methods for treatment of non-small cell lung cancer | RHIZEN PHARMACEUTICALS SA (CH) | 2019-01-08 | — | — | US | claimed |
| EP-2509974-B1 | PYRAZOLES DERIVATIVES MODULATORS OF CALCIUM RELEASE-ACTIVATED CALCIUM CHANNEL AND METHODS FOR TREATMENT OF NON-SMALL CELL LUNG CANCER | RHIZEN PHARMACEUTICALS S A (CH) | 2018-04-11 | — | — | EP | claimed |
| US-20150291588-A1 | NOVEL MODULATORS OF CALCIUM RELEASE-ACTIVATED CALCIUM CHANNEL AND METHODS FOR TREATMENT OF NON-SMALL CELL LUNG CANCER | RHIZEN PHARMACEUTICALS SA (CH) | 2015-10-15 | — | — | US | claimed |
| CN-104788430-A | Pyrazoles derivatives modulators of calcium release-activated calcium channel and methods for treatment of non-small cell lung cancer | INCOZEN THERAPEUTICS PVT LTD | 2015-07-22 | — | — | CN | claimed |
| CN-102958925-B | Pyrazole derivative calcium release-activated calcium channel modulators and methods of treating non-small cell lung cancer | RHIZEN PHARMACEUTICALS SA | 2015-04-15 | — | — | CN | claimed |
| US-8993612-B2 | Modulators of calcium release-activated calcium channel and methods for treatment of non-small cell lung cancer | RHIZEN PHARMACEUTICALS SA (CH) | 2015-03-31 | — | — | US | claimed |
| CN-102958925-A | Pyrazole derivative calcium release-activated calcium channel modulators and methods of treating non-small cell lung cancer | RHIZEN PHARMACEUTICALS SA | 2013-03-06 | — | — | CN | claimed |
| US-20110112058-A1 | NOVEL MODULATORS OF CALCIUM RELEASE-ACTIVATED CALCIUM CHANNEL AND METHODS FOR TREATMENT OF NON-SMALL CELL LUNG CANCER | INCOZEN THERAPEUTICS PVT. LTD. (IN) | 2011-05-12 | — | — | US | claimed |
| US-12544371-B2 | Methods and compositions for treating acute lung injury and acute respiratory distress syndrome | CALCIMEDICA, INC. (US) | 2026-02-10 | — | — | US | disclosed |
| US-20250120969-A1 | METHODS AND COMPOSITIONS FOR TREATING INFLAMMATION INJURY IN THE LUNGS | AVENUE CAPITAL MANAGEMENT II, L.P. | 2025-04-17 | — | — | US | disclosed |
| EP-4465988-A1 | METHODS AND COMPOSITIONS FOR TREATING INFLAMMATION INJURY IN THE LUNGS | Calcimedica, Inc. (US) | 2024-11-27 | — | — | EP | disclosed |
| CN-118871110-A | Methods and compositions for treating inflammatory lesions of the lung | 钙医学公司 | 2024-10-29 | — | — | CN | disclosed |
| EP-2509974-A1 | PYRAZOLES DERIVATIVES MODULATORS OF CALCIUM RELEASE -ACTIVATED CALCIUM CHANNEL AND METHODS FOR TREATMENT OF NON- SMALL CELL LUNG CANCER | Rhizen Pharmaceuticals S.A. (CH) | 2012-10-17 | — | — | EP | disclosed |
| US-20110112058-A1 | NOVEL MODULATORS OF CALCIUM RELEASE-ACTIVATED CALCIUM CHANNEL AND METHODS FOR TREATMENT OF NON-SMALL CELL LUNG CANCER | INCOZEN THERAPEUTICS PVT. LTD. (IN) | 2011-05-12 | — | — | US | disclosed |
| US-20110112058-A1 | NOVEL MODULATORS OF CALCIUM RELEASE-ACTIVATED CALCIUM CHANNEL AND METHODS FOR TREATMENT OF NON-SMALL CELL LUNG CANCER | INCOZEN THERAPEUTICS PVT. LTD. (IN) | 2011-05-12 | — | — | US | disclosed |
| WO-2011042798-A1 | PYRAZOLES DERIVATIVES MODULATORS OF CALCIUM RELEASE -ACTIVATED CALCIUM CHANNEL AND METHODS FOR TREATMENT OF NON- SMALL CELL LUNG CANCER | INCOZEN THERAPEUTICS PVT. LTD. (IN) | 2011-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12544371-B2 | Methods and compositions for treating acute lung injury and acute respiratory distress syndrome | ORAI1, MAVS, CASR | ORAI1 1/4885CRACR2A 80/4885NPC1 3859/4885 |
| US-20110112058-A1 | NOVEL MODULATORS OF CALCIUM RELEASE-ACTIVATED CALCIUM CHANNEL AND METHODS FOR TREATMENT OF NON-SMALL CELL LUNG CANCER | ORAI1, CACNB2, CACNB1 | ORAI1 1/4885CRACR2A 53/4885NPC1 2254/4885 |
| US-20250120969-A1 | METHODS AND COMPOSITIONS FOR TREATING INFLAMMATION INJURY IN THE LUNGS | IL1B, MAVS, MMP8 | ORAI1 92/4885CRACR2A 160/4885NPC1 4241/4885 |
| US-20190248791-A1 | NOVEL MODULATORS OF CALCIUM RELEASE-ACTIVATED CALCIUM CHANNEL AND METHODS FOR TREATMENT OF NON-SMALL CELL LUNG CANCER | ORAI1, CACNB2, CACNB1 | ORAI1 1/4885CRACR2A 53/4885NPC1 2254/4885 |
| US-20150291588-A1 | NOVEL MODULATORS OF CALCIUM RELEASE-ACTIVATED CALCIUM CHANNEL AND METHODS FOR TREATMENT OF NON-SMALL CELL LUNG CANCER | ORAI1, CACNB2, CACNB1 | ORAI1 1/4885CRACR2A 53/4885NPC1 2254/4885 |
| US-10174034-B2 | Modulators of calcium release-activated calcium channel and methods for treatment of non-small cell lung cancer | ORAI1, CACNA1E, CACNB2 | ORAI1 1/4885CRACR2A 55/4885NPC1 1656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.